←
Ghayas Issa153 posts
Ghayas Issa avatar

Ghayas Issa

@GhayasIssa

Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.

◷ Joined April 2017▧ 4 Photos and videos
Ghayas Issa avatar
Ghayas Issa@GhayasIssa·15 Mar 2023

Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature nature.com/articles/s41586-0… @MDAndersonNews

The Cancer Letter avatar
⟳ Ghayas Issa retweeted
The Cancer Letter@TheCancerLetter·22 Nov 2024

Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews). cancerletter.com/trials-and-…

Ghayas Issa avatar
Ghayas Issa@GhayasIssa·15 Nov 2024

Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)

Post attachment
Ghayas Issa avatar
Ghayas Issa@GhayasIssa·5 Nov 2024

The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD

We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration @GhayasIssa @MDAndersonNews

0:59
Ghayas Issa avatar
Ghayas Issa@GhayasIssa·9 Aug 2024

Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval ascopubs.org/doi/10.1200/JCO…

Andy Lane avatar
⟳ Ghayas Issa retweeted
Andy Lane@lane_andy·1 Aug 2024

How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley @DanaFarber #HemeNeoDivision ashpublications.org/blood/ar…

Nature Reviews Drug Discovery avatar
⟳ Ghayas Issa retweeted
Nature Reviews Drug Discovery@NatRevDrugDisc·21 Jun 2024

Menin inhibitors seek to debut as newest targeted therapy for leukaemia bit.ly/3xsRP99 Find out how small molecules that block a key protein–protein interaction could change the treatment landscape for many patients with acute leukaemias in this news article

Post attachment
Ghayas Issa avatar
Ghayas Issa@GhayasIssa·31 May 2024

Asciminib frontline!

NEJM@NEJM31 May 2024

Presented at #ASCO24: ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. nej.md/4bNNr3c

Post attachment